AFFILIATED CENTERS ACCOUNT FOR 30 PERCENT OF NATION’S TRANSFUSION REQUIREMENTS
NEWTOWN, Penn. (March 1, 2010) - Quotient Biodiagnostics, Inc., today announced that it has entered into an agreement with Blood Centers of America (BCA) as a preferred vendor. BCA will actively promote Quotient’s product line to its 38 blood center member organizations, which account for 35 percent of the nation’s transfusion requirements. The deal will include Quotient’s first 15 monoclonal antibodies in its proprietary line of manual transfusion diagnostics as well as future products when approved by the FDA and available.
Key elements of BCA's decision to name Quotient Biodiagnostics to its preferred vendor list include Quotient’s 30 years of experience producing high quality manual transfusion diagnostics products, its global reputation for innovation, its focus on customer service and its commitment to cost effectiveness.
"This partnership with Blood Centers of America is an exciting and important opportunity, as it helps Quotient Biodiagnostics to better access and serve BCA’s extensive blood center membership," said Jeremy Stackawitz, President and CEO, Quotient Biodiagnostics. "We look forward to working with BCA and their membership to introduce Quotient Biodiagnostics’ high-quality, cost-effective products in combination with our superior customer service experience.
Formed in 2009 to bring its products to the US market, Quotient Biodiagnostics sells its proprietary line of antisera products under the trade name ALBAclone®. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions at a reasonable cost.
Quotient Biodiagnostics’ current portfolio includes products used in forward blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-D, Anti-E, and Anti-c, as well as some rare anti-sera including Anti-k, Anti-M, Anti-N, Anti- Lea, Anti-Leb, and Anti-Lub – all monoclonal antibodies. Quotient also has two specialty products in its initial portfolio including the ALBAclone®Advanced Partial RhD Typing Kit which identifies weak and partial RhD types with results comparable to molecular analysis at a fraction of the cost, and the Quant-Rho® FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. In addition, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete its full portfolio of manual reagents of nearly 60 products.
"BCA selected Quotient Biodiagnostics as one of its preferred vendors for transfusion diagnostics after our thorough review of their product line, their commitment to customer service, and positive meeting with their senior management," says Charlie Mosher, BCA’s President. "We appreciate their long experience outside the United States and their commitment to excellence and value. We are also interested in working with them closely as they expand their product line that can help meet the needs of our Members."
Since announcing its expansion into the U.S. transfusion market in 2009, Quotient Biodiagnostics has made significant progress in building its customer base and product use, supported by its more than 30 years of experience in Europe and other markets, quality manufacturing and commitment to service excellence.
Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visitwww.quotientbd.com, or call the customer service line 888-284-1901, or e-mail email@example.com.
About Quotient Biodiagnostics
Quotient Biodiagnostics is the diagnostics division of Quotient Bioscience Group (United Kingdom), and through its wholly owned subsidiary, Alba Bioscience, brings over 30 years of experience in the transfusion medicine market to the Group. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient’s goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation (initially in North America) to market and sell the Group’s blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.